NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
0.9200
Dollar change
-0.0199
Percentage change
-2.12
%
Index- P/E- EPS (ttm)-352.42 Insider Own0.80% Shs Outstand5.46M Perf Week9.92%
Market Cap5.02M Forward P/E- EPS next Y-1.15 Insider Trans0.00% Shs Float5.42M Perf Month-8.91%
Enterprise Value-7.82M PEG- EPS next Q-0.80 Inst Own0.74% Short Float8.51% Perf Quarter-26.40%
Income-15.61M P/S- EPS this Y92.28% Inst Trans-2.87% Short Ratio0.27 Perf Half Y-83.72%
Sales0.00M P/B0.25 EPS next Y61.67% ROA-202.65% Short Interest0.46M Perf YTD-84.72%
Book/sh3.73 P/C0.38 EPS next 5Y70.98% ROE-477.53% 52W High148.00 -99.38% Perf Year-98.70%
Cash/sh2.39 P/FCF- EPS past 3/5Y90.20% 70.59% ROIC-142.34% 52W Low0.73 25.98% Perf 3Y-100.00%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility12.65% 9.12% Perf 5Y-100.00%
Dividend TTM- EV/Sales- EPS Y/Y TTM95.95% Oper. Margin- ATR (14)0.10 Perf 10Y-
Dividend Ex-Date- Quick Ratio4.93 Sales Y/Y TTM- Profit Margin- RSI (14)48.84 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio4.93 EPS Q/Q99.84% SMA205.15% Beta0.75 Target Price7.00
Payout- Debt/Eq0.02 Sales Q/Q- SMA50-10.03% Rel Volume0.04 Prev Close0.94
Employees5 LT Debt/Eq0.00 EarningsMay 15 AMC SMA200-76.14% Avg Volume1.71M Price0.92
IPONov 08, 2019 Option/ShortNo / Yes EPS/Sales Surpr.21.00% - Trades Volume71,025 Change-2.12%
Date Action Analyst Rating Change Price Target Change
Dec-28-20Downgrade Ladenburg Thalmann Buy → Neutral
Aug-24-20Initiated Ladenburg Thalmann Buy $11
Jun-24-25 09:15AM
Jun-05-25 08:05AM
May-16-25 08:05AM
May-13-25 09:35AM
07:00AM
08:46AM Loading…
Apr-02-25 08:46AM
Mar-25-25 08:00AM
Feb-26-25 09:05AM
Feb-20-25 09:00AM
Feb-19-25 09:00AM
08:30AM
Feb-18-25 09:00AM
Feb-10-25 08:00AM
Dec-05-24 09:10AM
09:10AM
09:00AM Loading…
Nov-25-24 09:00AM
Nov-18-24 08:55AM
Nov-15-24 09:10AM
Nov-04-24 09:15AM
Nov-01-24 09:00AM
Oct-23-24 02:50PM
Oct-10-24 09:00AM
Oct-08-24 09:15AM
Sep-23-24 09:00AM
Sep-12-24 09:00AM
Sep-04-24 09:05AM
Sep-03-24 08:00AM
Aug-27-24 09:10AM
Aug-22-24 09:15AM
Aug-15-24 08:00AM
07:00AM Loading…
Jul-30-24 07:00AM
Jul-25-24 09:05AM
Jul-16-24 09:15AM
Jul-11-24 07:29AM
Jul-03-24 11:10AM
Jun-26-24 08:00AM
Jun-14-24 03:11PM
Jun-10-24 08:00AM
Jun-03-24 08:05AM
May-20-24 08:30AM
May-16-24 11:53AM
07:45AM
Apr-23-24 09:00AM
Apr-22-24 10:15AM
Apr-01-24 11:52PM
05:00PM
09:05AM
Jan-29-24 09:00PM
Jan-18-24 08:45AM
Jan-17-24 08:45AM
Dec-18-23 08:35AM
Dec-06-23 09:00AM
Nov-22-23 09:05AM
Nov-16-23 10:00AM
Nov-15-23 08:00AM
Oct-19-23 09:05AM
Oct-18-23 10:00AM
Oct-16-23 09:00AM
Oct-11-23 08:45AM
Sep-07-23 08:45AM
Sep-05-23 08:45AM
Aug-14-23 08:35AM
07:35AM
Aug-03-23 08:15AM
08:00AM
Jul-27-23 09:05AM
Jul-05-23 08:45AM
Jun-14-23 09:05AM
May-25-23 09:05AM
May-15-23 08:35AM
May-08-23 08:45AM
May-03-23 08:45AM
Apr-27-23 08:45AM
Apr-17-23 06:54AM
Apr-10-23 08:45AM
Apr-06-23 09:05AM
Apr-03-23 08:05AM
Mar-29-23 09:05AM
Mar-13-23 07:05AM
Mar-09-23 09:05AM
Feb-07-23 08:45AM
Jan-12-23 08:45AM
Jan-11-23 01:00PM
Jan-05-23 09:05AM
Jan-03-23 02:28PM
12:00PM
Dec-08-22 09:08AM
Dec-05-22 08:05AM
Nov-30-22 10:00PM
Nov-28-22 04:53PM
Nov-15-22 01:09PM
Nov-14-22 04:05PM
Nov-02-22 08:45AM
Oct-10-22 09:00AM
Oct-07-22 08:00AM
Sep-28-22 09:05AM
Sep-23-22 09:00AM
Sep-07-22 08:45AM
Aug-15-22 08:05AM
Jul-25-22 08:05AM
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.